IMAI MedTech GmbH

Cancer causes millions of deaths each year. 2D histopathology, the main method for detecting cancer in tissue, involves the analysis of thin tissue slices. However, only a small percentage is examined, leading to false-negative results. The consequences are poor decisions, suboptimal treatments, and cancer recurrence. More accurate diagnosis significantly improves survival. We aim to push toward the transition to digital and 3D histopathology to overcome limitations and improve diagnosis. Team: Co-founders: Dr. Francesca Catto (biomedicine), Dr. Robert Axelrod (life sciences), Sascha Brun (robotic engineering). Our platform automates the processing of 3D tissue samples, enabling more accurate spatial imaging and analysis in 2 days. The histology market size was USD 12.3 B in 2020.